Illumina Accelerator

Pandora Biosciences operates as a neuroscience company.

Nusantics is a biotechnology company based in Jakarta, Indonesia, founded in 2019. The company specializes in precision molecular diagnostics, focusing on analyzing microbiome profiles to enhance healthcare outcomes in both human and animal applications. Nusantics offers a diverse range of products, including single pathogen molecular diagnostics, syndromic molecular diagnostics, and microbiome diagnostics utilizing PCR and Next Generation Sequencing technologies. By addressing areas such as respiratory and reproductive health, as well as blood-borne pathogens, the company aims to close the diagnostics gap and promote preventive healthcare, particularly in low- and middle-income countries. Additionally, Nusantics provides microbiome profiling services tailored for the skincare, personal care, food, and beverage industries.

Terrapeutics Pharma specializes in drug discovery, utilizing an innovative platform that screens for therapeutic molecules derived from soil. This technology is grounded in the principles of nature, allowing for the identification of small therapeutic molecules aimed at addressing challenging medical targets. The company's focus includes the development of inhibitors for the ascending reticular activating system (RAS), as well as advancing drug discovery for infectious diseases. Through this approach, Terrapeutics aims to provide healthcare professionals with effective tools for combating various health challenges.

Dama Health is a company specializing in pharmacogenetic technology aimed at providing personalized contraception recommendations for women and their clinicians. It leverages genetic testing in conjunction with an automated matching system that considers women's preferences, medical histories, and specific needs. By analyzing genetic predispositions, efficacy, and side effect profiles, Dama Health enables women and healthcare providers to make informed decisions regarding contraception, ensuring that individuals receive tailored options that align with their unique requirements.

Viridian Seeds creates super-legumes to provide a sustainable source of healthy, nutritious plant proteins.

Acrobat Genomics specializes in developing precise, high-throughput CRISPR-based gene editing technologies for creating innovative therapies.

CRISP-HR a therapeutics company has developed a proprietary, next-generation CRISPR platform to create novel therapeutics for rare diseases.

Rethink Bio, an Indian synthetic biology company, specializes in developing sustainable food solutions using microalgae. Their platform aims to create nutritious, delicious, and eco-friendly food products, harnessing the untapped potential of microalgae for a healthier planet and people.

Cache is a biotechnology company focused on developing a groundbreaking wet operating system designed for the storage, access, and computation of biomolecules at scale. By ensuring the integrity and fidelity of nucleic acids from various sources, Cache enables researchers and partners to accelerate molecular pathology research and gain insights into life sciences. This innovative approach facilitates the analysis of biomolecules, thereby unlocking new precision medicine applications and enhancing the capacity for understanding biological data. Ultimately, Cache aims to make both digital and biological data universally accessible and sustainable, eliminating the need for data deletion or disposal.

B4X, INC., a therapeutics and diagnostics company from Atlanta, Georgia, is utilizing multi-omic big data anchored in genomics to deliver life-saving therapeutics and precision diagnostics to individuals suffering from debilitating diseases of the brain.

Purpose Health, Inc. a mental wellness company from Northern Virginia, supports consumers on their mental wellness journey with data-driven insights into the physiological impact of stress on the microbiome and body.

NonExomics is a healthcare data analytics company that focuses on diagnosing and curing diseases by integrating genomics, transcriptomics, and proteomics data. The company employs proprietary machine learning techniques to predict the structures of nonexomic proteins and identify disease-specific nonexomic targets. This innovative approach supports researchers in their efforts to discover cures for rare diseases by providing valuable insights and prioritizing potential targets for further investigation. NonExomics aims to enhance the understanding of complex biological processes and facilitate advancements in medical research and treatment.

4SR Biosciences Inc. is a diagnostics and therapeutics company based on technology developed at the University of Chicago. The company specializes in exploring novel tRNA-based modalities for identifying disease biomarkers and developing cancer therapeutics. Its innovative platform employs RNA sequencing to analyze cellular tRNA, fragments, and modifications extracted from various clinical samples, including tissue, biofluids, and nasal swabs. This approach allows researchers to compare the biological properties of numerous microbes with distinct tRNA genes, facilitating the early detection of cancer.

EpiCombi.AI is a genomics signature–driven therapeutics company spun out of Oxford University that uses artificial intelligence to develop network-acting, multi-target drugs. The platform analyzes genomic and epigenetic data to generate drug predictions, identify key signals and targets, and optimize research workflows, enabling faster discovery for cancer and other diseases.

Genegoggle is a precision medicine biotech company focused on developing innovative therapeutics and diagnostic systems to enhance human health. The company specializes in creating advanced particles that can accurately differentiate between cancerous and healthy cells. By utilizing multi-dimensional genomic and epigenetic elements, Genegoggle aims to design next-generation compounds for drug discovery. Its approach incorporates artificial intelligence in genomic applications to target cancer cells effectively while minimizing damage to healthy tissues. This enables the development of novel therapeutics that provide patients with improved options for diagnosis and treatment, ultimately contributing to better health outcomes.

Solena is a biotechnology company focused on the microbiome of agricultural soils. It develops technologies to understand, preserve, and calibrate soil diversity with the goal of increasing agricultural production and farmer profitability through tailored biological inputs. The company offers tools to measure and assess soil biological capital, including a sampling kit that provides measurement and valuation results. By applying these insights, Solena aims to enable a sustainable and environmentally friendly approach to farming, optimizing the biological capital of soils to support productive, resilient crops.

ImYoo is focused on creating a patient-centric biodiscovery ecosystem that integrates high-resolution assays with user convenience. The company has developed a platform that enables the collection of scalable, high-fidelity, longitudinal data through single-cell multi-omic analysis of small blood volumes that can be self-collected at home. This innovative approach allows users to identify critical biomarkers from longitudinal samples, particularly during significant health events such as autoimmune flares or adverse therapeutic side effects. By prioritizing patient engagement and accessibility, ImYoo aims to advance the field of biodiscovery and enhance the understanding of individual health dynamics.

Bixbio is a biotechnology company focused on harnessing Africa's diverse genetic data to advance precision medicine. It employs artificial intelligence and machine learning to create comprehensive genetic datasets, facilitating the identification of disease-related genetic variants and novel drug targets.

NewStem is a Jerusalem-based biotechnology company specializing in precision medicine aimed at enhancing the effectiveness of chemotherapy. As a spinoff of Yissum, the Technology Transfer Company of The Hebrew University, NewStem has developed a unique platform that predicts patient resistance to chemotherapy, facilitating more targeted and effective cancer treatment options. The company employs synthetic lethal interaction principles and bioinformatics-based software to drive the discovery and development of anti-cancer therapies. This innovative approach positions NewStem at the forefront of regenerative medicine and cancer research, providing valuable tools for medical researchers to improve patient outcomes in cancer therapy.

Yali Biosciences is a food tech company focused on utilizing synthetic biology and genomics to develop climate-smart and sustainable food options. The company operates a synthetic biology platform that leverages computational biology to design and produce specialized fats aimed at enhancing alternative dairy products. By prioritizing renewable resources, Yali Biosciences enables the food industry to create delicious and sustainable alternatives to traditional dairy, contributing to ecological responsibility within the sector.

Parallel Health is a skin health company that uses genomics, the skin microbiome, and machine learning to offer end-to-end dermatology solutions. It develops a precision health platform that combines microbial genomics, big data, and AI to enable skin testing, personalized microbiome products, and custom prescriptions for consumers, patients, and clinicians, integrating derm telehealth, microbiome diagnostics, and data-driven skincare therapies to address diverse skin conditions with tailored treatments.

Broken String Biosciences is focused on developing a novel sequencing platform aimed at assessing genome stability to enhance the safety and efficacy of cell and gene therapies. By integrating advanced sequencing techniques with bioinformatics analysis and artificial intelligence, the company provides healthcare professionals with a comprehensive, data-driven approach to medicine. This innovative platform is designed to facilitate the development of the next generation of therapies, ensuring they are safer by design and capable of addressing various medical challenges. Through its efforts, Broken String Biosciences aims to unlock new possibilities in the realm of advanced therapeutic solutions.

Flightpath Biosciences is a biotechnology company based in Berkeley, California, founded in 2019. It specializes in developing innovative therapies aimed at treating rare infectious diseases, particularly those caused by pathogenic bacteria. The company's focus includes antibiotic therapies that target co-infectious bacteria in conditions such as Lyme disease, aiming to reduce microbiome damage and address multiple pathogenic bacteria in both the oral and gut microbiomes. By collaborating with leading scientists and experts in therapeutics and diagnostics across various academic institutions and government agencies, Flightpath Biosciences is committed to exploring diverse fields of biology to create novel and targeted treatment solutions.

MultiplAI Health is a biotechnology company that focuses on enhancing disease detection through advanced blood screening tests. Utilizing RNA sequencing and artificial intelligence, the company analyzes a wide array of biomarkers in whole blood samples to identify complex diseases, including cardiovascular disorders and cancers. This innovative approach allows for universal remote screening, enabling both preventative assessments and post-treatment monitoring. The simplicity of a liquid biopsy means that tests can be conducted anywhere with just a blood sample, making them accessible and cost-effective compared to traditional diagnostic methods. By facilitating earlier detection of diseases in asymptomatic individuals, MultiplAI Health aims to improve patient prognoses and treatment strategies through more accurate diagnostic insights.

Rubik Therapeutics is a biotechnology company focused on developing next-generation cell therapies for solid tumors. It employs a computational engine and genome-scale discovery tools to identify genetic modulators that enable T and NK cells to exhibit potent and selective anti-tumor activity. The company advances a portfolio of selective cancer targets and leverages immune cell signaling to counteract immune suppression, pursuing safer and more effective treatments for solid cancers with high unmet medical need.

Biotax specializes in biological and genomic informatics, offering advanced technologies and services to pharmaceutical companies, hospitals, and medical centers. Founded by prominent researchers, the company aims to improve patient outcomes through innovative diagnostics and treatment protocols, focusing on microbiome genetics analysis using artificial intelligence and genomic informatics for personalized medicine.

Oshun Medical is an innovative diagnostic and digital health company exclusively committed to advancing the health of women and championing awareness of their healthcare issues.

Algen Biotechnologies, Inc. is a therapeutic discovery company focused on drug development through an innovative platform that decodes functional gene networks. The company leverages advanced technologies, including CRISPR and machine learning, to uncover disease-driving RNA messages. By analyzing complex disease signaling and gene networks, Algen aims to facilitate drug discovery for cancer and other diseases with significant unmet medical needs. Its approach seeks to provide valuable insights for drug companies, enabling them to identify and develop effective treatments.

Biome Makers Inc. is a biotechnology company based in San Francisco, California, specializing in the identification and understanding of microbiomes, particularly in agricultural contexts. Founded in 2015, the company employs advanced DNA sequencing technologies and proprietary Intelligent Computing systems to deliver detailed, crop-specific insights and recommendations. This innovative approach enables growers and manufacturers to analyze soil ecosystems effectively, enhancing agricultural production and product quality through data-driven insights. By simplifying complex microbiome data, Biome Makers supports its customers in optimizing their agricultural practices and improving overall outcomes.

Trace Genomics specializes in soil health and microbiome analysis, employing DNA sequencing and artificial intelligence to provide a soil microbiome test that enables early prediction of soil diseases, soil health, and crop quality. The company analyzes microbial composition and quantifies microbes, indexing this data and comparing it with soil chemistry to generate actionable insights for agronomists and corporate partners. Its platform integrates biology and chemistry data to help farmers optimize input use, improve yields, and manage risk, treating soil as a valuable asset. By mapping the soil microbiome, Trace Genomics aims to support sustainable agriculture through informed management decisions.

MetaMixis Inc. specializes in the development of enzymes and metabolic pathways for microorganisms that produce chemicals. Founded in 2012 and headquartered in Vancouver, Canada, the company leverages its expertise in synthetic biology, environmental genomics, and bioinformatics to revolutionize enzyme and pathway discovery. MetaMixis creates biosensors that utilize an environment's inherent capabilities to detect biochemical transformations. Additionally, it screens diverse environmental DNA libraries to generate a multi-candidate portfolio of enzymes and pathways designed for specific target transformations. The company aims to contribute to the bioeconomy by advancing innovative solutions in biochemistry and sustainability.

Vitagene, Inc. is a health technology company that utilizes genomic science and advanced technology to deliver personalized healthcare solutions. Founded in 2014 and based in San Francisco, the company offers a DNA-based personalization platform that helps physicians provide data-driven care. Vitagene's algorithm generates tailored supplement regimens and analyzes extensive patient data, including genetics, blood work, and lifestyle factors, to create customized nutritional plans. Additionally, the company produces DNA health test kits and at-home COVID-19 saliva test kits. It also provides comprehensive health and ancestry reports that encompass diet, exercise, and supplementation insights, ensuring that individuals receive recommendations that align with their specific health needs and goals.

NextGen Jane is a data-driven women's health company that focuses on enhancing reproductive health through innovative diagnostic tools. The company has developed a smart tampon system that enables users to conveniently collect and mail in cells from the reproductive tract shed during menstruation. Utilizing patented tampon collection technology, NextGen Jane transforms biological samples from the endometrium, cervix, fallopian tubes, and ovaries into digital diagnoses. This process allows for in-depth sequencing analysis and the prediction of reproductive diseases, providing women with valuable insights into their reproductive health in a hassle-free manner.

Biome Makers Inc. is a biotechnology company based in San Francisco, California, specializing in the identification and understanding of microbiomes, particularly in agricultural contexts. Founded in 2015, the company employs advanced DNA sequencing technologies and proprietary Intelligent Computing systems to deliver detailed, crop-specific insights and recommendations. This innovative approach enables growers and manufacturers to analyze soil ecosystems effectively, enhancing agricultural production and product quality through data-driven insights. By simplifying complex microbiome data, Biome Makers supports its customers in optimizing their agricultural practices and improving overall outcomes.

A genomics company, developing noninvasive urine-based nucleic acid sequencing diagnostics for the detection and monitoring of cancer.

Xcell Biosciences, Inc. is a San Francisco-based life science company founded in 2012, specializing in innovative technologies for cancer research and immunotherapy. The company has developed proprietary systems that capture, grow, and analyze cancer cells directly from patient blood samples, allowing for precise control over primary cell phenotype and function. This technology enhances the development and production of cell therapies, providing scientists with advanced tools for cell maintenance, expansion, and optimization. By supporting various primary cell types, including immune, stem, and tumor cells, Xcell Biosciences aims to improve predictive therapy development and clinical outcomes for patients undergoing immunotherapy.

Encoded Therapeutics is a biotechnology company focused on precision gene therapies to treat a broad range of severe genetic disorders. It develops therapies and a platform that identifies human genome sequences that regulate gene expression using screening and computational approaches. The company's pipeline targets conditions across multiple pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular disease, aiming to help medical practitioners treat patients and improve outcomes. Based in South San Francisco, California, Encoded Therapeutics was founded in 2014 and was previously known as Encoded Genomics.

EpiBiome, Inc. is a precision microbiome engineering company based in South San Francisco, California, founded in 2013. The company is dedicated to developing therapies that address infectious diseases in humans and agriculture without relying on small-molecule antibiotics. EpiBiome focuses on phage therapy, which targets specific strains within the microbiome, effectively treating antibiotic-resistant infections. Its applications include treatment for mastitis in dairy cows and addressing infections caused by Escherichia coli in humans. By utilizing advanced sequencing and bioinformatic processes, EpiBiome aims to identify pathogenic bacteria and microbiome changes that contribute to disease, offering innovative alternatives to combat the rising threat of antibiotic resistance. As of July 2018, it operates as a subsidiary of Locus Biosciences, Inc.